Outlook Therapeutics Inc (OTLK)

02:37 AM

Outlook Therapeutics Inc. Stock Analysis and ForecastRapidly expanding wealth - Autocar Professional

02:37 AM

05:41 AM

What analysts say about Outlook Therapeutics Inc. stockFree Capital Growth Strategies - Autocar Professional

05:41 AM

Jul 22, 2025

Outlook Therapeutics Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference - GlobeNewswire

Jul 22, 2025

Jul 22, 2025

Outlook Therapeutics Participates in the Virtual Investor 'What’s Your Story” Summer Spotlight On-Demand Conference - The Manila Times

Jul 22, 2025

Jul 22, 2025

Exclusive: Outlook Therapeutics' New CEO Bob Jahr Reveals Growth Strategy for Retina Disease Treatment - Stock Titan

Jul 22, 2025

Jul 21, 2025

What drives Outlook Therapeutics Inc. stock priceSignificant capital appreciation - Autocar Professional

Jul 21, 2025

Jul 20, 2025

Is Outlook Therapeutics Inc. a good long term investmentOutstanding growth strategies - Autocar Professional

Jul 20, 2025

Jul 18, 2025

Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) biggest owners are retail investors who got richer after stock soared 14% last week - simplywall.st

Jul 18, 2025

Jul 17, 2025

Outlook Therapeutics(OTLK) Drops 4.15% Amid Biotech Volatility - AInvest

Jul 17, 2025

Jul 15, 2025

How Outlook Therapeutics Inc. stock performs during market volatilityCapital Doubling Tips - Newser

Jul 15, 2025

Jul 15, 2025

Why Outlook Therapeutics Inc. stock attracts strong analyst attentionTop Momentum Stock Pick - Newser

Jul 15, 2025

Jul 15, 2025

What makes Outlook Therapeutics Inc. stock price move sharplyFree Expert-Led Investment Training - Newser

Jul 15, 2025

Jul 14, 2025

Outlook Therapeutics (OTLK) Soars 12.08% on Clinical Trial Success - AInvest

Jul 14, 2025

Jul 14, 2025

Oncobiologics, Inc. (NASDAQ:OTLK) Receives $9.60 Consensus PT from Analysts - Defense World

Jul 14, 2025

Jul 09, 2025

Outlook Therapeutics shares rise 3.12% intraday after recent Federal Circuit's Disclosure-Level Test In In Re Riggs. - AInvest

Jul 09, 2025

Jul 08, 2025

What caused OTLK's net profit surge in Q3 2024? - AInvest

Jul 08, 2025

Jul 08, 2025

SHAREHOLDER ALERT: Contact Levi & Korsinsky Before January 2, 2024 to Discuss Your RightsOTLK - ACCESS Newswire

Jul 08, 2025

Jul 04, 2025

Outlook Therapeutics announces CEO appointment - MSN

Jul 04, 2025

Jul 03, 2025

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Outlook Therapeutics, Inc.(OTLK) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

Jul 03, 2025

Jul 03, 2025

INVESTOR ALERT: Levi & Korsinsky Notifies Outlook Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineOTLK - ACCESS Newswire

Jul 03, 2025

Jul 02, 2025

SHAREHOLDER ALERT: Potential Recovery for Outlook Therapeutics, Inc. (OTLK) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

Jul 02, 2025

Jul 02, 2025

Outlook Therapeutics Appoints New CEO Robert Charles Jahr - The Globe and Mail

Jul 02, 2025

Jul 01, 2025

Outlook Therapeutics Appoints Bob Jahr as CEO - citybiz

Jul 01, 2025

Jul 01, 2025

Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer | OTLK Stock News - GuruFocus

Jul 01, 2025

Jul 01, 2025

Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer - The Manila Times

Jul 01, 2025

Jun 30, 2025

Outlook Therapeutics, Inc.(NasdaqCM: OTLK) dropped from Russell 2500 Growth Index - MarketScreener

Jun 30, 2025

Jun 18, 2025

Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event | OTLK Stock News - GuruFocus

Jun 18, 2025

Jun 18, 2025

Outlook Therapeutics, Inc. to Host Virtual Investor Lunch Break Event on June 25, 2025 - Nasdaq

Jun 18, 2025

Jun 18, 2025

Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event - GlobeNewswire

Jun 18, 2025

Jun 18, 2025

Outlook Therapeutics CEO Reveals Commercial Strategy and Key Milestones in Exclusive Investor Event - Stock Titan

Jun 18, 2025

Jun 17, 2025

SHAREHOLDER ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 2, 2024 in Outlook LawsuitOTLK - ACCESS Newswire

Jun 17, 2025

Jun 16, 2025

Outlook Launches Ophthalmic Bevacizumab In Germany And The UK - insights.citeline.com

Jun 16, 2025

Jun 16, 2025

Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World

Jun 16, 2025

Jun 13, 2025

Outlook Therapeutics Requests to Dismiss Class Action Filed by Investors - TradingView

Jun 13, 2025

Jun 13, 2025

Brookline Capital lowers Outlook Therapeutics stock price target on cash balance By Investing.com - Investing.com South Africa

Jun 13, 2025

Jun 13, 2025

Brookline Capital lowers Outlook Therapeutics stock price target on cash balance - Investing.com Australia

Jun 13, 2025

Jun 10, 2025

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ - GuruFocus

Jun 10, 2025

Jun 10, 2025

Outlook Therapeutics Announces SMC Recommendation Of LYTENAVA For Treatment Of Wet AMD - MarketScreener

Jun 10, 2025

Jun 10, 2025

Outlook Therapeutics (OTLK) Gains SMC Approval for LYTENAVA in Scotland | OTLK Stock News - GuruFocus

Jun 10, 2025

Jun 10, 2025

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD - The Manila Times

Jun 10, 2025